This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sullivan DJ, Franchini M, Senefeld JW, Joyner MJ, Casadevall A, Focosi D. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ1.1 and XBB. J Gen Virol. 2023. https://doi.org/10.1101/2022.11.25.517977.
Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F, et al. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2023;37:1175–85.
Casadevall A, Joyner MJ, Pirofski LA, Senefeld JW, Shoham S, Sullivan D, et al. Convalescent plasma therapy in COVID-19: unravelling the data using the principles of antibody therapy. Expert Rev Respir Med. 2023;17:381–95.
Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer. 2023;4:96–107.
Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis. JAMA Netw Open. 2022;6:e2250647.
Food and Drug Administration (FDA). Fact sheet for health care providers: emergency use authorization (EUA) of COVID-19 convalescent plasma for treatment of coronavirus disease 2019 (COVID-19). 2021. https://www.fda.gov/media/141478/download.
Cesaro S, Ljungman P, Mikulska M, Hirsch HH, von Lilienfeld-Toal M, Cordonnier C, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2022;36:147–1480.
National Comprehensive Cancer Network (NCCN). NCCN Guidelines Version 2.2022. Prevention and treatment of cancer-related infections. 2022. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf.
Bloch EM, Focosi D, Shoham S, Senefeld J, Tobian AAR, Baden LR, et al. Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19. Clin Infect Dis. 2023;76:2018–24.
Hoertel N, Boulware DR, Sánchez-Rico M, Burgun A, Limosin F. Prevalence of contraindications to nirmatrelvir-ritonavir among hospitalized patients with COVID-19 at risk for progression to severe disease. JAMA Netw Open. 2022;5:e2242140.
Author information
Authors and Affiliations
Contributions
DF and MF designed the study and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Focosi, D., Franchini, M. COVID-19 convalescent plasma retains value for immunocompromised patients. Leukemia 37, 1762–1763 (2023). https://doi.org/10.1038/s41375-023-01939-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-023-01939-4